Nitinol Stent Implantation in TASC A and B Superficial Femoral Artery Lesions:The Femoral Artery Conformexx Trial (FACT)
- 1 August 2008
- journal article
- research article
- Published by International Society of Endovascular Specialists in Journal of Endovascular Therapy
- Vol. 15 (4), 390-398
- https://doi.org/10.1583/08-2461.1
Abstract
To investigate the impact of nitinol stenting of superficial femoral artery (SFA) lesions with a maximum length of 10 cm (TASC-II A or B) on 1-year outcomes compared to a historical study cohort from the Femoral Artery Stent Trial (FAST). Between January 2004 and August 2005, 6 study sites enrolled 110 symptomatic patients (75 men; mean age 68±9 years) with a single de novo >70% SFA lesion 1-class change in Rutherford category, and major adverse events. Data were analyzed according to the intention-to-treat principle and according to the actual treatment received (“on treatment” analysis). Outcomes were compared to the historical balloon angioplasty (BA) arm and the Luminexx 3 stent arm of the randomized FAST study. Technical success was achieved in 106 (96%) patients; at 1 year, the primary endpoint of ultrasound-assessed binary restenosis was reached in 14 (23.3%) of 60 patients (95% CI 13.4% to 36%). This restenosis rate was lower versus the historical BA (38.6%, p=0.057) or Luminexx 3 stent controls (31.7%, p=0.284) from FAST. The clinically driven TLR was 7.4% (7 of 94 clinically controlled patients), which was also lower compared to 18.3% (p=0.098) and 14.9% (p=0.267) for the historical BA and Luminexx 3 stent groups, respectively. The mean Rutherford category was reduced from 2.75±0.79 to 0.94±1.38 (p<0.0001); 85.1% were improved by at least 1 Rutherford category. The ABI increased from 0.62±0.15 to 0.85±0.20 (p<0.0001). This study of patients with SFA lesions documented favorable outcomes using nitinol stents in TASC-II A or B lesions after 1 year. The study was underpowered to prove superiority of the Conformexx nitinol stent design compared to historical balloon only or Luminexx 3 stent groups.Keywords
This publication has 12 references indexed in Scilit:
- Nitinol Stent Implantation Versus Percutaneous Transluminal Angioplasty in Superficial Femoral Artery Lesions up to 10 cm in LengthCirculation, 2007
- Sustained Benefit at 2 Years of Primary Femoropopliteal Stenting Compared With Balloon Angioplasty With Optional StentingCirculation, 2007
- Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery:Long-term Results From the SIROCCO TrialJournal of Endovascular Therapy, 2006
- Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral ArteryNew England Journal of Medicine, 2006
- ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)Circulation, 2006
- Prevalence and clinical impact of stent fractures after femoropopliteal stentingJournal of the American College of Cardiology, 2005
- Primary Patency of Femoropopliteal Arteries Treated with Nitinol versus Stainless Steel Self-expanding Stents: Propensity Score–adjusted AnalysisRadiology, 2004
- Transcatheter Interventions for the Treatment of Peripheral Atherosclerotic Lesions: Part IJournal of Vascular and Interventional Radiology, 2001
- Recommended standards for reports dealing with lower extremity ischemia: Revised versionJournal of Vascular Surgery, 1997
- Duplex scanning of the peripheral arteries: Correlation of the peak velocity ratio with angiographic diameter reductionJapanese Journal of Clinical Oncology, 1992